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Abstract
Bone morphogenetic proteins (BMPs) are growth factors that exert important functions in cell
proliferation, migration and differentiation. Till date, multiple human tumors have been reported
to display a dysregulation of several members of the BMP pathway that is associated with
enhanced malignant tumor growth and metastasis. BMPER (BMP endothelial cell precursor-
derived regulator) is a direct BMP modulator that is necessary for BMPs to exert their full-range
signaling activity. Moreover, BMPER is expressed by endothelial cells and their progenitors, and
has pro-angiogenic features in these cells. Here, we describe the expression of BMPER in human
specimens of lung, colon and cervix carcinomas and cell lines derived from such carcinomas. In
contrast to healthy tissues, BMPER is highly expressed upon malignant deterioration.
Functionally, loss of BMPER in the lung tumor cell line A549 impairs proliferation, migration,
invasion as well as tumor cell-induced endothelial cell sprout formation. In contrast, stimulation of
A549 cells with exogenous BMPER had no further effect. We found that the BMPER effect may
be transduced by regulation of the BMP target transcription factor inhibitor of DNA binding 1
(Id1) and matrix metalloproteinases (MMPs) 9 and 2. These facilitators of cell migration are
down-regulated when BMPER is absent. To prove the relevance of our in vitro results in vivo, we
generated Lewis lung carcinoma cells with impaired BMPER expression and implanted them into
the lungs of C57BL/6 mice. In this model, the absence of BMPER resulted in severely reduced
tumor growth and tumor angiogenesis. Taken together, these data unequivocally demonstrate that
the BMP modulator BMPER is highly expressed in malignant tumors and tumor growth is
dependent on the presence of BMPER.
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The transforming growth factor-beta family of growth factors has been subject of intense
research efforts as it becomes more and more evident that perturbation of this pathway is
accompanied by the promotion of malignant cell behavior (Hanahan and Weinberg, 2011).
Bone morphogenetic proteins (BMPs) form an important subfamily of the transforming
growth factor-beta family. Besides their developmental expression, BMPs are expressed in
various tumor types including melanoma (Rothhammer et al., 2005), pancreas (Gordon et
al., 2009), prostate (Yang et al., 2005; Buijs et al., 2007b), breast (Buijs et al., 2007a;
Katsuno et al., 2008), renal (Blish et al., 2008), liver (Maegdefrau et al., 2009; Wu et al.,
2011), ovary (Moll et al., 2006), lung (Langenfeld et al., 2006) and colon carcinoma (Deng
et al., 2007; Thawani et al., 2010). The role of BMPs in tumor biology is controversially
discussed. Several studies have shown that BMPs can either inhibit or promote tumor
progression and metastasis (Alarmo and Kallioniemi, 2010). For example, BMP2 has been
shown to inhibit tumorigenesis of breast cancer cells (Pouliot and Labrie, 2002),
medulloblastoma (Zhao et al., 2008), or prostate cancer cells (Soda et al., 1998). On the
contrary, BMP2 was reported to promote tumorigenesis of breast carcinoma (Raida et al.,
2005), osteosarcoma (Arihiro and Inai, 2001; Weiss et al., 2006), prostate cancer (Feeley et
al., 2005) and lung cancer (Langenfeld et al., 2003, 2006) (for a further review of BMPs and
cancer, please refer to Thawani et al., 2010).
BMPs are extracellular proteins that signal through cell-surface complexes of type I and type
II serine/threonine kinase receptors (Moser and Patterson, 2005). Upon activation, the
receptors mediate intracellular signaling via the Id transcription factors involving the Smad
1/5 transcription factors (Schmierer and Hill, 2007). For instance, BMP2 activates Smad1/5
which is a prerequisite of increased cell proliferation (Langenfeld et al., 2006). Furthermore,
BMPs can activate other signaling cascades such as the Erk1/2 pathway to ascertain a
closely controlled regulation of cell proliferation and survival (Zhou et al., 2007; Balmanno
and Cook, 2009). The impact of BMPs on cell proliferation is also controlled by other
pathways, for example, by control of cyclin-dependent kinases (Klose et al., 2011).
BMPs are functionally modulated by extracellular binding proteins, such as Chordin
(Piccolo et al., 1996), Noggin (Smith and Harland, 1992), Drm/Gremlin (Stabile et al.,
2007), Cerberus/Caronte (Piccolo et al., 1999; Yu et al., 2008), Follistatin (Yamashita et al.,
1995; Iemura et al., 1998), uterine sensitization-associated gene-1 (Laurikkala et al., 2003;
Yanagita et al., 2004), Sclerostin (Brunkow et al., 2001; Krause et al., 2010), twisted
gastrulation (Tsg) (Oelgeschlager et al., 2000) and BMP endothelial cell precursor derived
regulator (BMPER) (Moser et al., 2003). (For further review of extracellular BMP
modulators please refer to Balemans and Van Hul, 2002; Umulis et al., 2009). BMPER is
known to bind and modulate at least three BMPs (BMP-2, -4 and -6), and was originally
identified in a screen for differentially expressed proteins in embryonic endothelial precursor
cells. BMPER is a secreted glycoprotein that contains five cysteine-rich domains followed
by a von Willebrand D domain and a trypsin-inhibitor domain (Moser et al., 2003). We and
others recently demonstrated that BMPER may enhance BMP signaling in a concentration-
dependent fashion (Heinke et al., 2008; Serpe et al., 2008). Loss-of-function models reveal
that BMPER has the ability to act as a pro-BMP modulator most likely by facilitating BMP
binding to their respective receptors (Conley et al., 2000; Ikeya et al., 2006; Rentzsch et al.,
2006; Heinke et al., 2008; Serpe et al., 2008). Here, we characterize the expression and
function of BMPER in the context of malignant disease.
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BMPER is highly expressed in human lung, colon and cervix adenocarcinomas
On the basis of reported evidence that BMP signaling is an important regulator of malignant
disease, we set out to investigate the expression and function of the BMP modulator
BMPER in tumors. As a first step, we analyzed the expression of BMPER in various human
carcinomas by immunohistochemistry. As shown in Figure 1, BMPER is strongly expressed
in lung, colon and cervix carcinoma specimens, whereas its expression is low in the
respective normal tissues. Consistent with our previous data that BMPER is a secreted
protein, we found BMPER expression predominantly in the cytoplasm of tumor cells and in
the intercellular space. These data show that BMPER is highly upregulated in tumors and
encouraged us to investigate BMPER in the context of malignant cell behavior in more
detail.
BMPER is expressed in human carcinoma cell lines
In order to allow for in vitro functional experiments using tumor cell lines, we explored
BMPER expression in established tumor cell lines of different tissue origin. The highest
levels of BMPER RNA were detected in A549 (lung adenocarcinoma) and HeLa (cervix
adenocarcinoma) cells. BMPER RNA was also detectable in CaCo-2 (colon
adenocarcinoma) and HepG2 (hepatocellular carcinoma) cells (Figure 2a). Using
immunocytochemistry staining, we found that BMPER protein is present in the cytoplasm of
cultured tumor cell lines (Figure 2b). This finding is consistent with our
immunohistochemistry findings from human specimens. The localization of BMPER
expression is also in agreement with reports that BMPER is detectable in late endosomes
during embryonic development (Kelley et al., 2009). Thus, BMPER is highly expressed in
the cytoplasm of tumor cells.
BMPER regulates tumor cell proliferation, cell migration and invasion
Next, we asked for the functional role of BMPER in tumors. Knowing that BMPs enhance
cell proliferation and that BMPER is a crucial regulator of BMP pathway activity in
endothelial cells, we investigated if BMPER regulates cell proliferation of tumor cells using
the BrdU-incorporation method. When BMPER was added to A549 (Figure 3a) or HeLa
cells (Supplementary Figure 1A), no change of proliferation rates occurred. Next, we aimed
to investigate if loss of BMPER may influence tumor-cell proliferation. Therefore, BMPER
was depleted using two different BMPER-specific siRNAs and proliferation was assessed in
A549 cells, which express high levels of BMPER endogenously. In these cells, BMPER-
specific siRNA transfection reduced BMPER expression by up to 80% (Supplementary
Figure 4A), and resulted in markedly reduced tumor cell proliferation as shown in Figure 3b.
This data suggests that both endogenous BMPER expression levels and cell proliferation
rates are high in tumor cells even before supplementation with recombinant BMPER, and
thus, proliferation cannot be increased beyond this level by supplementation of additional
BMPER. But vice versa, when BMPER is depleted tumor cell proliferation is markedly
reduced.
Besides cell proliferation, migration and invasive growth capacity of cells are also important
features of malignant cell behavior. To investigate the role of BMPER in tumor cell
migration and invasion, we performed transmigration experiments using a modified Boyden
chamber system. Stimulation of cells with epidermal growth factor (EGF) served as a
positive control. A549 tumor cell migration remained unchanged supporting the notion that
the effect of endogenous BMPER cannot be further enhanced by addition of exogenous
BMPER (Figure 3c). Vice versa and similar to what we found for cell proliferation, when
BMPER was depleted from cells, their migratory capacity was reduced by 36% (Figure 3d).
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To support this hypothesis, we performed additional migration and proliferation assays with
the liver-cell carcinoma cell line HepG2, which endogenously expresses low levels of
BMPER (Figure 2a). Indeed, HepG2 cells respond to stimulation with exogenous BMPER
protein in a concentration-dependent increase of migration (Figure 3f) and proliferation
(Figure 3g).
The fact that cell proliferation and migration are dependent on BMPER, led us to ask if the
invasive capacity as the final common pathway of malignant cell behavior may be controlled
by BMPER as well. To elucidate this question, cells were seeded into a modified Boyden
chamber system coated with matrigel to mimic extracellular matrix (ECM). Indeed, when
BMPER was silenced by siBMPER, cell invasion was reduced to an average of 73% in
A549 cells compared with control siRNA (Figure 3e). To rule out a cell type-specific effect,
the experiment was repeated with HeLa cells, and similar results were obtained
(Supplementary Figures 1A–E). Mechanistically, we hypothesized that BMPs may be
involved in induction of migration and proliferation of cells. Therefore, we performed
similar experiments in the presence of the endogenous BMP antagonist Noggin or the small
molecule BMP receptor antagonist dorsomorphin. Indeed, proliferation and migration of
A549 cells were significantly reduced by both BMP antagonists suggesting that BMP
signaling is involved in these cell functions (Supplementary Figures 2A and B). Taken
together, exogenous BMPER cannot further enhance cell proliferation and migration in
tumor cells that already express high levels of endogenous BMPER. However, cell functions
that contribute to malignant cell behavior, such as proliferation, migration and ECM
invasion, are dependent on the presence of BMPER.
Tumor cell-derived BMPER regulates endothelial cell function
Having found that BMPER controls important tumor cell functions, we next aimed to
investigate if tumor cell-derived BMPER may control the function of surrounding
endothelial cells and thereby angiogenesis. Human umbilical vein endothelial cells
(HUVECs) were analyzed for their capacity to sprout, migrate and form branches, when
cultured with conditioned media from tumor cells in which BMPER had been depleted.
Under these conditions, HUVEC sprouting was reduced by 48% compared with endothelial
cells cultured with conditioned media from control cells (Figures 4a–c). Similarly,
endothelial cell migration was significantly inhibited when HUVECs were incubated with
conditioned media from BMPER-depleted tumor cells (LLCmBMPER79 or
LLCmBMPER80) compared with conditioned media from control cells (LLCscrCont)
(Figure 4d). These experiments were repeated with supernatants obtained from HeLa cells
and similar results were obtained (Supplementary Figures 1F–G). Thus, when tumor cells
express BMPER, their supernatant confers proangiogenic activity to adjacent endothelial
cells.
To investigate if this effect is conferred by BMPER contained in the media, we analyzed the
activity of BMP-responsive signaling cascades in HUVECs. However, there was no
activation of Smad1/5 or Erk1/2 signaling pathways under these conditions (data not
shown). A second possibility is that tumor cells produce angiogenic factors that are reduced
in the absence of BMPER from the tumor cells. To test this hypothesis, we decided to
perform a ‘proteome-profiler human angiogenesis antibody array’ of control and BMPER-
knocked-down A549 cells (Figure 4e). Indeed, loss of BMPER decreases vascular
endothelial growth factor (VEGF) expression to 50% of control levels. Moreover,
expression of anti-angiogenic proteins, such as Endostatin, PAI-1 and Thrombospondin-1 is
increased in the absence of BMPER.
Together these data demonstrate that BMPER affects the angiogenic proteome of tumor
cells that in turn forces endothelial cells to acquire a less angiogenic phenotype.
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BMPER regulates the expression of matrix-degrading enzymes
To investigate a potential mechanism for increased tumor cell migration and sprouting, we
asked if BMPER might modulate the expression of matrix metalloproteinases (MMPs).
Generally, MMPs are required to facilitate migratory and invasive processes during tumor
growth (Egeblad and Werb, 2002). When BMPER was silenced in A549 cells, MMP-9 and
MMP-2 were indeed downregulated, whereas MMPs-1, -3, and -13 remained unaffected
(Figures 5a and b and data not shown). Consequently, MMP-2 activity in cell culture
supernatants of BMPER silenced A549 cells was reduced as quantified by zymography
(Figure 5c). To rule out a cell line-specific effect in A549 cells, we repeated these
experiments in HeLa cells and found similar results (Supplementary Figures 3A–C). Thus,
loss of BMPER is accompanied by reduced MMP activity.
Loss of BMPER reduces BMP pathway activity as reflected by Id1 expression
BMPER is a known modulator of BMP pathway activity in endothelial cells. We have
shown earlier that BMPER may exert pro- or anti- BMP effects in a dose-dependent fashion.
Now, we aimed to elucidate in which direction BMPER modulates BMP activity in tumor
cells. We chose the transcription factor Id1, a well-characterized read-out for BMP pathway
activity (Miyazono and Miyazawa, 2002; Fidler, 2003; ten Dijke et al., 2003), to assess
BMPER effect on BMP pathway activity in tumor cells. When BMPER was silenced, Id1
expression was significantly reduced as detected on the RNA and protein levels (Figures 5d,
e and Supplementary Figures 3D and E). Thus, loss of BMPER results in inhibition of BMP
pathway activity, indicating that endogenous BMPER behaves as a pro-BMP mediator.
Loss of BMPER results in reduced tumor growth in vivo
Given our in vitro results that tumor cell proliferation and invasion are dependent on the
presence of BMPER, our next goal was to investigate if these modifications in cell behavior
result in changes in tumor growth in vivo. Therefore, we generated three different Lewis
lung carcinoma (LLC) cell lines that stably express either of two different shRNAs
specifically targeted against BMPER (mBMPER79 or mBMPER80) or a scrambled control
shRNA (ScrCont) using lentiviral transduction. After clonal selection, significant inhibition
of BMPER protein was confirmed (Supplementary Figure 4C). First, we functionally
assessed these cell lines in vitro. Indeed, LLCmBMPER79 and LLCmBMPER80 cells
behaved as expected from our previous experiments using siRNA transfections in A549
cells: Id1 expression was reduced, and proliferation was inhibited in LLCmBMPER79 and
LLCmBMPER80 compared with in LLCScrControl cells (Supplementary Figure 4D and
Figure 6a). To address the effect of loss of BMPER on tumor growth in vivo, 1 × 104 LLC
cells were implanted into the left lung of C57BL/6 mice, respectively. After 14 days, mice
were euthanized and tumor sizes were quantified. We observed significant differences in
tumor size between tumors derived from BMPER-depleted LLCs (LLCmBMPER79,
LLCmBMPER80) and tumors derived from LLCScrControl cells. Volumetric quantification
revealed that control tumors were about eightfold larger than BMPER-depleted tumors
(Figures 6b and c). Taken together, depletion of BMPER results in reduction of tumor
growth in vivo.
Loss of BMPER results in reduced tumor vessel density in vivo
Given our in vitro results that endothelial cell sprouting and branching are dependent on the
presence of BMPER in tumor cells, our next goal was to investigate changes in tumor-
derived angiogenesis in vivo. Tumor vascularization was determined at the time of autopsy
on day 14 after implantation of LLC. Endothelial cells were visualized in tumor sections by
immunofluorescence using an antibody directed against CD31 (Figure 7). Indeed, in tumors
derived from LLCmBMPER79 and LLCmBMPER80, vessel density is significantly
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decreased to 50% compared with LLCScrControl. Thus, loss of BMPER in tumor cells
results in inhibition of tumor angiogenesis in vivo.
Discussion
In the present work, we found that tumor cell growth is strongly reduced in the absence of
the extracellular BMP modulator BMPER, in vitro and in vivo. Mechanistically, we
demonstrate that tumor cell growth and proliferation, BMP pathway activity, MMP
expression and tumor angiogenesis are inhibited when BMPER is lacking.
As outlined in the introduction, the effect of BMPs on cancer cells is complex. On one hand,
it is well documented that activation of the BMP pathway is associated with enhanced tumor
progression; however, on the other hand, there are also reports that BMP pathway activation
may have the potential to inhibit tumor cell proliferation, migration and angiogenesis.
Certainly, dose effects and the respective local signaling context are variables that need to be
taken into account to explain these discrepancies. Generally, the activity of BMP signaling
can be regulated by extracellular modulators (Balemans and Van Hul, 2002). This
mechanism is also in place in tumors and has consequences on tumor cell growth. For
instance, the classical BMP antagonist Chordin is almost absent in epithelial ovarian cancers
compared with normal tissues allowing for a dominant proliferative effect of BMPs. Vice
versa, when Chordin is added to malignant cells in vitro, their invasive and migratory
behavior is attenuated (Moll et al., 2006). Similarly, stable overexpression of Chordin leads
to reduced migration and invasion of melanoma cells and consequently, to reduced tumor
growth in vivo (Rothhammer et al., 2007). Along the same line of argument, when Noggin,
another extracellular BMP antagonist, is added to lung carcinoma cells it bears anti-
proliferative potential (Langenfeld et al., 2003). Several groups have shown that the
presence of the downstream transcription factor of the BMP-pathway Id1 is associated with
more aggressive, invasive cancer phenotypes (Ling et al., 2005; Langenfeld et al., 2006;
Gautschi et al., 2008) and several tumors are dependent on the presence of Id1 or Id3 to
grow at all (Lyden et al., 1999). Altogether, these findings suggest that in several malignant
tumors the balance between pro- and anti-BMP factors is disturbed. One may speculate that
the reconstitution of normal BMP signaling will at least inhibit tumor growth and may
furthermore contribute to antagonize the malignant phenotype (Bailey et al., 2007).
In this context, our findings that BMPER is expressed at high levels in tumors in vitro and in
vivo (Figures 1 and 2) are of particular interest because BMPER has been shown earlier to
act as a BMP modulator (Heinke et al., 2008; Serpe et al., 2008). BMPER is part of a
positive feedback loop that contributes to enhance local BMP activity, as shown in zebrafish
and Drosophila (Rentzsch et al., 2006; Serpe et al., 2008). Here, we show that BMPER also
plays a functional role in tumor cell biology. BMPER controls features of malignant cell
behavior, such as cell proliferation and migration, as shown in loss-of-function experiments
(Figures 3, 4 and 6). These results hold true in all tumor cell lines that we have investigated,
suggesting a general role of BMPER in malignant cell behavior. Interestingly, it has been
reported that in immune-resistant tumor cells BMPER expression is highly upregulated
confirming our notion that BMPER expression is a feature of a highly malignant tumor
phenotype (Lin et al., 2007). The functional role of BMPER in tumor cells is similar to its
role in endothelial cells. In these cells, BMPER has an activating effect and controls the
activity of the prototypical BMP agonist BMP4 (Heinke et al., 2008). The data presented
here support the notion that endogenous BMPER is a general BMP enhancer not only in
endothelial but also in tumor cells (Figure 5).
Malignant cell behavior downstream of BMP signaling is conferred—at least in part—by
modulation of MMP activity. To enable detachment of tumor cells for invasion and
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metastasis, ECM is subjected to degradation by MMPs (Fidler, 2003; Thiery and Sleeman,
2006). Moreover, MMPs contribute to angiogenesis by exposing cryptic pro-angiogenic
integrin-binding sites in the ECM and by releasing ECM-bound angiogenic growth factors
such as VEGF (Bergers et al., 2000). In pancreatic tumor cells, upregulation of MMP-2
through Smad signaling induces their invasiveness (Gordon et al., 2009). In contrast,
inhibition of BMP4 impairs MMP expression in melanoma cells (Rothhammer et al., 2008).
Here we report a regulatory relationship between BMPER and MMPs that may contribute to
explain the effect of BMPER on tumor cell behavior. When BMPER is silenced in tumor
cells, MMP-9 and MMP-2 are downregulated (Figure 5). As a consequence, ECM cannot be
processed properly to allow for tumor growth and metastasis explaining impaired tumor cell
migration and invasion in the absence of BMPER.
Another important mechanism of tumor cell growth is angiogenesis (Hanahan and
Weinberg, 2011). BMPs do not only enhance tumor proliferation but are also necessary to
establish a vascular network for the growing tumor (Bailey et al., 2007; Rothhammer et al.,
2007; Goumans et al., 2009). Along the same line of argument, we and others have shown
that BMPs promote angiogenesis and capillary sprouting during embryonic development
and in adulthood (Valdimarsdottir et al., 2002; Langenfeld and Langenfeld, 2004; Zhou et
al., 2007). Recently, we reported that BMPER is a key regulator of BMPs in endothelial
cells during angiogenesis in vitro and in vivo (Heinke et al., 2008). It has pro-angiogenic
functions and is necessary for BMP4 to exert its activating role on endothelial cells (Heinke
et al., 2008). Here, we show that tumor cells that have been depleted from BMPER are less
potent to induce angiogenesis, most likely by shifting the balance of pro- and antiangiogenic
factors expressed by these cells (Figure 4). VEGF is downregulated whereas anti-angiogenic
proteins such as Endostatin, PAI-1 and Thrombospondin-1 are upregulated. These findings
are functionally in line with reports that BMPs may upregulate VEGF (Deckers et al., 2002).
Another mechanism of modulation of angiogenesis by BMPER is its modulatory role on
MMPs, which are necessary not only for tumor cell invasiveness but also for angiogenesis
(Orlichenko and Radisky, 2008; Huang et al., 2009).
Summary and conclusion
Taken together, BMPER is expressed in adenocarcinomas of the lung, colorectum and
cervix and is necessary for their invasive behavior. Regarding tumor progression, BMPER is
important in two ways: for the tumor cells themselves to promote growth and malignant cell
behavior and also for stimulation of tumor-associated angiogenesis. Thus, BMPER may be a
promising target for future anti-tumor therapy.
Materials and methods
Further details and additional methods are provided as Supplementary Information.
Cell culture and reagents
Detailed descriptions of cell culture and patient samples are provided in the Supplementary
Materials and Methods.
RNA interference
BMPER-siRNAs I and II were purchased from Invitrogen, Karlsruhe, Germany. The
sequences are available in the Supplementary Material and Methods Online. Scrambled
negative control-Alexa Fluor 488 nm was purchased from Qiagen, Hilden, Germany. For
transfection, a final concentration of 100 nmol/l siRNA together with Lipofectamine
RNAiMAX was used according to the manufacturer’s reverse transfection protocol
(Invitrogen).
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RNA extraction and reverse transcription
DNA-free total RNA was extracted from A549, CaCo-2, HeLa and HepG2 cells using the
Aurum RNA Mini Kit (Bio-Rad, Munich, Germany). Reverse transcriptions were performed
with iScript cDNA-Kit applying 1 μg RNA following the manufacturer’s protocol (Bio-
Rad).
Semiquantitative and real-time PCR
Reverse transcription-PCR analysis was performed as described previously (Heinke et al.,
2008).
Quantitative real-time PCR analysis following RNA interference was performed using IQ
SybrGreen 2 × Supermix and the iCycler real-time PCR detection system (Bio-Rad). Primer
sequences are available in the Supplementary Material and Methods. Quantification was
performed using MyiQ light-cycler software (Bio-Rad). Knockdown efficiency was
calculated using the ΔΔCT method (Wong and Medrano, 2005). The housekeeping gene
hRP was used for internal normalization.
Western blot analysis
Antibodies against BMPER (monoclonal rat ab; R&D systems, Wiesbaden, Germany), Id1
(polyclonal rabbit ab; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH
(polyclonal rabbit ab; Millipore, Schwalbach, Germany) were used and western blot analysis
performed as previously described (Heinke et al., 2008).
Gelatin zymography
The method was performed as previously described by Gordon et al. (2009). Details are
given in the Supplementary Materials and Methods.
Proteome profiler human angiogenesis antibody array
Protein expression analysis of A549 cells treated with siRNA control or BMPER siRNA (I
and II) was performed 48 h post transfection using the R&D Systems proteome profiler
human angiogenesis antibody array following the manufacturer’s instructions.
Proliferation assay
Proliferation was assessed using a colorimetric BrdU-incorporation ELISA (Roche,
Penzberg, Germany). At 24 h after siRNA transfection, cells were cultured in fresh BrdU-
containing medium for another 24 h. The colorimetric ELISA for BrdU quantification was
performed following the manufacturer’s instruction.
Migration assay
Cell migration assay was performed as previously described (Heinke et al., 2008).
Invasion assay
Cell invasion was examined using the BD tumor invasion system following the
manufacturer’s instructions (BD, Heidelberg, Germany).
Tumor cell supernatant-induced endothelial cell sprouting assay
At 24–48 h after siRNA transfection, A549 and HeLa cells were incubated with 1% fetal
bovine serum endothelial basal media. Subsequently, HUVECs were pretreated with these
tumor cell supernatants for 16–18 h and subjected to a matrigel assay as described
previously (Heinke et al., 2008).
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Orthotopic lung tumor implantation
The study conforms to the Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health, and was performed after securing appropriate
institutional approval. Log-phase cell cultures of LLC shRNA clones were harvested,
washed three times with PBS and resuspended at a cell density 6.6 × 105/ml. Mice were
anesthetized, 1 × 104 LLCs were mixed with 15 μl of matrigel and implanted into the lung
parenchyma, as previously described (Doki et al., 1999). At 14 days after tumor
implantation, animals were euthanized through cardiac perfusion. To estimate the tumor
volume as well as for histology, the lungs were removed and snap frozen in liquid nitrogen-
cooled N-methylbutane until further analysis.
Estimation of tumor volume and vascularization
Details are given in the Supplementary Materials and Methods.
Immunocytochemistry
A549, CaCo-2 and HeLa cells grown on Falcon four-well chamber slides (BD) and were
fixed in ice-cold methanol/acetone at −20 °C for 10 min. Afterwards, cells were incubated
over night at 4 °C with the monoclonal BMPER antibody (1:250; R&D Systems) or with
control ratIgG (Vector Laboratories, Burlingane, CA, USA), respectively. The staining was
completed with goat-anti rat-Cy3 (1:500; Chemicon International, Millipore). For
visualization of nuclei, slides were treated with DAPI (1:30 000; Sigma, Deisenhofen,
Germany). All photographs were taken with Zeiss Apotome and analyzed with Zeiss
Axiovision Rel. 4.7, Göttingen, Germany.
Immunohistochemistry
Details are given in the Supplementary Materials and Methods.
Statistical analysis and quantification
Statistical analysis was performed using GraphPad Prism 4.0, Graph Pad Software, La Jolla,
CA, USA. Data are presented as mean±s.d. and comparisons were calculated by Student’s t-
test (two-sided, unpaired). All experiments were repeated at least three times in triplicates.
Results were considered statistically significant for P<0.05. For in vivo experiments one-
way analysis of variance was performed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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BMPER is expressed in human lung, colorectal and cervix adenocarcinomas. Tissue
specimens of normal epithelium and invasive adenocarcinomas of the lung, colorectum and
cervix were analyzed for BMPER expression using immunohistochemistry (left panels).
BMPER expression is stained in purple. Cell nuclei were counterstained with hematoxylin
(blue). Staining of serial sections with rat IgG was used as negative control (right panels).
Scale bar, 100 μm.
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BMPER expression and localization in tumor cells. (a) Expression of BMPER mRNA in
human tumor cells lines of different origins was analyzed by reverse transcription-PCR.
A549 (lung adenocarcinoma), CaCo-2 (colon adenocarcinoma), HeLa (cervix
adenocarcinoma) and HepG2 (hepatocellular carcinoma) cells were analyzed using specific
primers for BMPER; hRP served as internal control. (b) Localization of BMPER protein by
immunocytochemistry in A549, CaCo-2 and HeLa cells (left panel). Rat IgG was used as
negative control (right panel). Nuclei were stained with DAPI. Scale bar, 20 μm.
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Impact of BMPER on carcinoma cell proliferation, migration and invasion. (a) Proliferation
was determined by BrdU assay. Triplicates of A549 cells were incubated for 24 h with BrdU
and increasing concentrations of BMPER. Cells with BrdU and medium served as negative
control. (b) A549 cells were transfected in triplicates with either one of two BMPER-
specific siRNAs or scrambled-siRNA control. At 48 h post transfection, the BrdU ELISA
was performed. (c) For trans-migration, A549 cells were serum-starved overnight and
assayed with or without BMPER at indicated concentrations or EGF (50 ng/ml final
concentration) as positive control. Triplicates were fixed after 4 h and five random
microscopic fields were counted. (d) A549 cells were transfected with either one of two
BMPER-specific siRNAs or scrambled siRNA control. Forty-eight hours post transfection
tumor cell migration was quantified. (e) At 24 h post transfection of A549 cells, cell
invasion into matrix was quantified. Triplicates were fixed after 24 h and five random
microscopic fields were counted, respectively. (f) Trans-migration assay of HepG2 cells
stimulated with recombinant BMPER protein at indicated concentrations. (g) Proliferation
was determined by BrdU assay. Triplicates of HepG2 cells were incubated for 24 h with
BrdU and increasing concentrations of BMPER. Cells with BrdU and medium served as
negative control. Mean±s.d.; *P<0.05 versus the respective control. hpf = high power field.
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Impact of BMPER knockdown in tumor cells on endothelial cell function. (a–c) BMPER
reduction in tumor cells effects tube formation of endothelial cells. HUVECs were incubated
with the supernatant of A549 cells, which were transfected with one of two specific siRNA
against BMPER or negative control siRNA, respectively. Thereafter, HUVECs were
subjected to matrigel assay. Representative micrographs of HUVECs stimulated with
supernatants of siRNA-transfected A549 cells are shown. Scale bar = 200 μm. (b)
Cumulative sprout length and (c) branch points of capillary-like structures were measured
after 3 h and quantified. Mean±s.d.; *P<0.001 versus control siRNA. (d) HUVEC migration
was assayed with the supernatants of LLC shRNA clones in the trans-migration assay.
Triplicates were fixed after 4 h and for each five random microscopic fields were counted.
Mean±s.d.; *P<0.001 versus ScrCont. (e) ‘Proteome-profiler human-angiogenesis antibody
array’ of control and BMPER-knocked down (I. and II.) of A549 cell lysates 48 h post
transfection of siRNAs.
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Lack of BMPER in A549 carcinoma cells modulates expression of MMPs and expression of
the BMP target gene Id1. (a, b and d) mRNA expression of MMP-2, MMP-9 and Id1 in
A549 cells after 24, 48 and 72 h post transfection with siRNA BMPER I or II was analyzed
compared with scrambled siRNA control. mRNA content was quantified by real-time
(q)PCR using specific primers for MMP-2, MMP-9, Id1 and hRP as internal control. Knock-
down efficiency was calculated using ΔΔCT method. Mean±s.d.; *P<0.05 versus control.
(c) Representative gelatin zymography assay of conditioned media collected from siRNA-
transfected A549 cells 72 h post transfection. MMPs degrade gelatin and produce a white
band in the coomassie-stained gelatin SDS gel. (e) Western blot analysis for Id1 was
performed 48 h post transfection. GAPDH served as loading control. Densitometric analysis
of Id protein expression for three independent experiments is shown. Mean±s.d.; *P<0.01
versus control.
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Mouse in vivo model of BMPER knockdown in LLC-2 cells. (a) Triplicates of three murine
LLC clones stable expressing either a scrambled shRNA (ScrCont) or one of two different
shRNAs targeted against BMPER (mBMPER79 or 80) were incubated for 24 h with BrdU
in serum-free medium. Afterwards, the BrdU ELISA was performed. Mean±s.d.; *P<0.01
versus the ScrCont. (b, c) LLC shRNA clones were implanted into the left lung of 8-week
old female C57BL/6 mice and tumor growth examined 2 weeks later. (b) Hematoxylin and
Eosin (HE)-stained representative cryosections of LLC shRNA clone tumors in mouse
lungs. Scale bar, 500 μm. (c) Macroscopic pictures and quantitative analysis of the tumor
volume (ScrCont and mBMPER79 n = 9/group, mBMPER80 n = 6/group; mean±s.d.;
*P<0.01 versus ScrCont).
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Vessel density of BMPER knock down LLC cells-derived tumors in vivo. (a)
Immunohistofluorescence of CD31 (red— endothelial cells) and DAPI (blue—nuclei)
stainings of representative cryosections from LLC shRNA tumors in mouse lungs. Scale bar
= 50 μm. (b) Quantitative analysis of tumor vessel density (n=5/group; mean±s.d.; *P<0.01
versus ScrCont).
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